Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 12, 2010, Pages 1490-1499

  Esposito, Federica ^a   Radaelli, Marta ^a   Martinelli, Vittorio ^a   Sormani, Maria Pia ^b   Martinelli Boneschi, Filippo ^a   Moiola, Lucia ^a   Rocca, Maria Assunta ^a   Rodegher, Mariaemma ^a   Comi, Giancarlo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

multiple sclerosis; relapsing remitting; secondary progressive

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GADOLINIUM; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; ALOPECIA; ARTICLE; ASTHENIA; BRAIN; BREAST CANCER; CANDIDURIA; CARDIOTOXICITY; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OPEN STUDY; PROSTATE CANCER; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOPHLEBITIS; THYROID TUMOR; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650093744     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510379613     Document Type: Article

References (37)

1. Fidler JM, DeJoy SQ, Smith III FR and Gibbons Jr JJ Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986 ; 136: 2747-2754.
2. Fidler JM, DeJoy SQ and Gibbons Jr JJ Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986 ; 137: 727-732.
3. Levine S. and Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986 ; 13: 175-181.
4. Mustafa M., Diener P., Sun JB, Link H. and Olsson T. Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity. Scand J Immunol 1993 ; 38: 499-507.
5. Morrissey SP, Le Page E. and Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005 ; 12: 74-87.
6. Lublin FD, Lavasa M., Viti C. and Knobler RL Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987 ; 45: 122-128.
7. Edan G., Miller D., Clanet M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997 ; 62: 112-118.
8. Millefiorini E., Gasperini C., Pozzilli C., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997 ; 244: 153-159.
9. Hartung HP, Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002 ; 360: 2018-2025.
10. Van de Wyngaert FA, Beguin C., D'Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001 ; 101: 210-216.
11. Martinelli Boneschi F., Rovaris M., Capra R. and Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005 ; 4: CD002127.
12. Cohen BA and Mikol DD Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004 ; 63: S28-32.
13. Ghalie RG, Edan G., Laurent M., et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002 ; 59: 909-913.
14. Neuhaus O., Kieseier BC and Hartung HP Mechanisms of mitoxantrone in multiple sclerosis-what is known? J Neurol Sci 2004 ; 223: 25-27.
15. Lassmann H., Bruck W. and Lucchinetti CF The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007 ; 17: 210-218.
16. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
17. Polman CH, Reingold SC, Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 2005 ; 58: 840-846.
18. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
19. Avvisati G., Lo Coco F., Diverio D., et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996 ; 88: 1390-1398.
20. Neuhaus O., Kieseier BC and Hartung HP Mitoxantrone (Novantrone) in multiple sclerosis: new insights. Expert Rev Neurother 2004 ; 4: 17-26.
21. Cocco E., Marchi P., Sardu C., et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007 ; 13: 975-980.
22. Debouverie M., Taillandier L., Pittion-Vouyovitch S., Louis S. and Vespignani H. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment. Mult Scler 2007 ; 13: 626-631.
23. Buttinelli C., Clemenzi A., Borriello G., Denaro F., Pozzilli C. and Fieschi C. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Eur J Neurol 2007 ; 14: 1281-1287.
24. Le Page E., Leray E., Taurin G., et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008 ; 79: 52-56.
25. Goodin DS, Arnason BG, Coyle PK, Frohman EM and Paty DW The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003 ; 61: 1332-1338.
26. Gauthier SA and Weiner HL Cyclophosphamide therapy for MS. Int MS J 2005 ; 12: 52-58.
27. Coles AJ, Cox A., Le Page E., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006 ; 253: 98-108.
28. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008 ; 359: 1786-1801.
29. Paul F., Dorr J., Wurfel J., Vogel HP and Zipp F. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007 ; 78: 198-200.
30. Ellis R. and Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009 ; 15: 505-508.
31. Vicari AM, Ciceri F., Folli F., et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998 ; 12: 441-442.
32. Pascual AM, Tellez N., Bosca I., et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009 ; 15: 1303-1310.
33. Martinelli V., Bellantonio P. and Bergamaschi R. Incidence of acute leukemia in multiple sclerosis patients treated with mitoxantrone: a multi-centre retrospective Italian study. American Academy of Neurology's 61st Annual Meeting in Seattle, WA, 25 April- 2 May, 2009.
34. Verdecchia A., Micheli A., Colonna M., Moreno V., Izarzugaza MI and Paci E. A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. Ann Oncol 2002 ; 13: 1128-1139.
35. Cavalla P., Rovei V., Masera S., et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 2006 ; 27: 231-239.
36. Johnson FR, Van Houtven G., Ozdemir S., et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol 2009 ; 256: 554-562.
37. Cotte S., von Ahsen N., Kruse N., et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009 ; 132: 2517-2530.